Atossa Therapeutics, Inc. (ATOS)
After hours:
| Previous Close | 1.4600 |
| Open | 1.4400 |
| Bid | 1.4400 x 400 |
| Ask | 1.4800 x 400 |
| Day's Range | 1.3800 - 1.5100 |
| 52 Week Range | 0.6200 - 2.3100 |
| Volume | |
| Avg. Volume | 1,016,295 |
| Market Cap | 183.605M |
| Beta (5Y Monthly) | 1.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
ZacksIs Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Here is how Atossa Genetics Inc. (ATOS) and CorMedix (CRMD) have performed compared to their sector so far this year.
GlobeNewswireAtossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer
FDA Update to Mammography Regulations in MQSA Final Rule is Effective TodaySEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced its support of the U.S. Food and Drug Administration (FDA) for issuing a final rule to update the mammography regulations issued under the Mammography Quality Standards Act of 1992 (MQSA), which becomes effective today. Among the updates, the final rule requires mammography facilities to provid
ZacksIs Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
Here is how Atossa Genetics Inc. (ATOS) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year.
